DiaMedica Therapeutics (DMAC) Research & Development (2018 - 2026)

DiaMedica Therapeutics (DMAC) has reported Research & Development for 9 consecutive years, with $8.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development rose 40.04% year-over-year to $8.2 million; the trailing twelve-month figure through Jun 2026 stood at $29.3 million (up 27.67% YoY), and the FY2025 full-year result was $24.6 million, up 29.16% from the prior year.
• Research & Development rose to $8.2 million in Q2 2026 per DMAC's latest filing, from $8.0 million in the prior quarter.
• Across five years, Research & Development topped out at $8.2 million in Q2 2026 and bottomed at $1.6 million in Q3 2022.
• Historically, Research & Development has averaged $4.5 million across 5 years, with a median of $3.8 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Research & Development dropped 29.67% in 2022, then jumped 99.51% in 2023.
• Over 5 years, Research & Development stood at $2.3 million in 2022, then jumped by 61.98% to $3.7 million in 2023, then surged by 75.96% to $6.5 million in 2024, then grew by 3.54% to $6.7 million in 2025, then climbed by 21.7% to $8.2 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $8.2 million, $8.0 million, and $6.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.